Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)

Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Suh M, Cheon G, Lee D,

Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,

#3025 Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (NEN): A Systematic Review and Meta-Analysis

Introduction: Several Phase-II trials have been designed to evaluate Tyrosine Kinase Inhibitor (TKI) and in particular Pazopanib in Neuroendocrine Neoplasia (NEN) but it’s efficacy is not yet demonstrated in a randomized Phase III trial.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bongiovanni A, Liverani C, Recine f, Fausti V, Mercatali L,

Keywords: pazopanib, neuroendocrine neoplasia, neuroendocrine tumors, meta-analysis, carcinoid,

#3018 Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?

Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Gertner J

Authors: Gertner J, Eastwood O, Furtado O'Mahony L, Quaglia E, McSweeney A,

Keywords: telotristat,

#2901 Data is Power - Registry Experience at an ENETS COE

Introduction: The collection of anonymised data for patients with neuroendocrine tumours is necessary for the ongoing improvement of patient care and research/clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hogg A

Authors: Hogg A, Stell A, Marusic P, Sinnott R, Cummins M,

Keywords: PROMS, mobile phone app, registry,

#2846 Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin

Introduction: Determining the origin of a neuroendocrine tumor (NET) of unknown primary can be challenging. Liver metastases can originate from any organ in the body, while pulmonary NETs can be metastases but also primary tumors. This especially holds true for Multiple Endocrine Neoplasia Type 1 patients, who often have multiple primary pancreatic and intestinal NETs. It is important to know the origin of the primary tumor since resection or ablation is crucial in case of treatment with curative intent. Furthermore, the site of origin determines prognosis, treatment options and eligibility for clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hackeng W, Geisenberger C, de Leng W, Morsink F, Vriens M,

Keywords: Methylation profiling, Neuroendocrine tumor, Machine Learning, Unknown Primary,